Pricing Log in Create free account

Cytokinetics, Incorporated (CYTK) vs TG Therapeutics, Inc. (TGTX)

Cytokinetics, Incorporated and TG Therapeutics, Inc. are both Biotechnology companies. TG Therapeutics, Inc. is the larger, with a market value of $8.9B against $7.7B — 1.1× the size. Cytokinetics, Incorporated has negative trailing earnings, so its P/E is not meaningful; TG Therapeutics, Inc. trades at 19.1×. TG Therapeutics, Inc. grew revenue faster over the last twelve months: 76.1% against 29.9%. TG Therapeutics, Inc. has the higher net margin (55.2% vs −686.6%) and the higher return on invested capital (10.7% vs 0.00%). Across the 17 metrics below, TG Therapeutics, Inc. leads on 14 and Cytokinetics, Incorporated on 3.

Valuation

Metric CYTK TGTX Biotechnology median
P/E n/m 19.11 10.26
P/S 64.40 10.30 9.18
P/B n/m 13.64 2.05
Price to free cash flow n/m 473.79 24.81
EV/EBITDA n/m 62.00 0.65
EV/Sales 65.85 10.54 8.98
Earnings yield (10.93%) 5.23% (34.89%)
Free cash flow yield (8.07%) 0.21% (24.52%)

Profitability

Metric CYTK TGTX Biotechnology median
Gross margin 0.00% 82.37% 65.16%
Operating margin (625.15%) 17.05% 0.00%
Net margin (686.63%) 55.22% 0.00%
Free cash flow margin (519.53%) 2.17% 0.00%
Return on equity 184.71% 100.28% (50.12%)
Return on assets (47.70%) 37.70% (45.60%)
Return on invested capital 0.00% 10.69% 0.00%

Growth

Metric CYTK TGTX Biotechnology median
Revenue growth (TTM) 29.90% 76.08% 6.26%
EPS growth (last fiscal year) (24.33%) 1,746.67% 29.88%
Revenue growth, 5-year CAGR 9.54% 426.73% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CYTK TGTX Biotechnology median
Debt to equity (0.54) 1.23 0.00
Current ratio 3.36 4.27 4.89
Net debt to EBITDA (0.46) 0.86 1.01

Dividend

Metric CYTK TGTX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CYTK TGTX Biotechnology median
Market cap 7.72b 8.87b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack